AN2 Therapeutics, Inc.

As of June 13, 2025, the market trend has shifted to mildly bearish due to bearish signals from daily moving averages and Bollinger Bands, despite a mildly bullish MACD and neutral RSI indicating weak momentum.

AN2 Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $11 million and a market cap of $35.61 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -58.80%.

As of Jun 18, AN2 Therapeutics, Inc. has a market capitalization of 35.61 million and reported net sales of 0.00 million with a net profit of -45.36 million over the last four quarters. As of Dec 24, the company's shareholder's funds were 81.85 million, and total assets were 92.09 million.